Edition:
United Kingdom

Medtronic PLC (MDT.N)

MDT.N on New York Stock Exchange

86.68USD
19 Jan 2018
Change (% chg)

$-0.58 (-0.66%)
Prev Close
$87.26
Open
$87.58
Day's High
$87.90
Day's Low
$86.04
Volume
2,078,915
Avg. Vol
1,466,026
52-wk High
$89.71
52-wk Low
$73.59

Select another date:

Tue, Jan 16 2018

BRIEF-Medtronic Receives FDA Clearance For Riptide Aspiration System

* MEDTRONIC RECEIVES FDA CLEARANCE FOR RIPTIDE(TM) ASPIRATION SYSTEM

BRIEF-FDA Approves Innovative Clinician Programmer For The Medtronic Synchromed II Intrathecal Drug Delivery System

* FDA APPROVES INNOVATIVE CLINICIAN PROGRAMMER FOR THE MEDTRONIC SYNCHROMED II INTRATHECAL DRUG DELIVERY SYSTEM FOR CHRONIC PAIN AND SEVERE SPASTICITY Source text for Eikon: Further company coverage:

Medtronic unveils restructuring plan

Medtronic Plc on Monday unveiled a restructuring plan that it expects will help it save $500 million to $700 million annually over the next five years.

Medtronic unveils restructuring plan

Jan 8 Medtronic Plc on Monday unveiled a restructuring plan that it expects will help it save $500 million to $700 million annually over the next five years.

BRIEF-Bob White Named President Of Medtronic's Minimally Invasive Therapies Group

* BOB WHITE NAMED EXECUTIVE VICE PRESIDENT AND PRESIDENT OF MEDTRONIC'S MINIMALLY INVASIVE THERAPIES GROUP; CHRIS LEE TO ASSUME LEADERSHIP OF MEDTRONIC'S ASIA PACIFIC REGION Source text for Eikon: Further company coverage:

Medtronic settles states' probe into Infuse marketing for $12 million

BOSTON Medtronic Plc has agreed to pay $12 million to resolve claims that the company engaged in a deceptive marketing strategy to promote its Infuse bone graft product used in spinal surgery, the Massachusetts attorney general said on Wednesday.

UPDATE 2-Medtronic settles states' probe into Infuse marketing for $12 mln

BOSTON, Dec 13 Medtronic Plc has agreed to pay $12 million to resolve claims that the company engaged in a deceptive marketing strategy to promote its Infuse bone graft product used in spinal surgery, the Massachusetts attorney general said on Wednesday.

Medtronic settles states' probe into Infuse marketing for $12 mln

BOSTON, Dec 13 Medtronic Plc has agreed to pay $12 million to resolve claims that the company engaged in a deceptive marketing strategy to promote its Infuse bone graft product used in spinal surgery, the Massachusetts attorney general said on Wednesday.

MEDTRONIC TO PAY $12 MILLION TO RESOLVE PROBE BY STATES INTO MARKETING OF INFUSE - MASSACHUSETTS ATTORNEY GENERAL

MEDTRONIC TO PAY $12 MILLION TO RESOLVE PROBE BY STATES INTO MARKETING OF INFUSE - MASSACHUSETTS ATTORNEY GENERAL

BRIEF-Medtronic Plc Says ‍Commenced Launch Of New Telehealth Solutions In Support Of Its National Contract Awarded By U.S. Department Of Veterans Affairs​

* MEDTRONIC PLC SAYS ‍COMMENCED LAUNCH OF NEW TELEHEALTH SOLUTIONS IN SUPPORT OF ITS NATIONAL CONTRACT AWARDED BY U.S. DEPARTMENT OF VETERANS AFFAIRS​ Source text for Eikon: Further company coverage:

Select another date: